EVUSHELD

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
IB/0019	B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol	11/10/2024		SmPC and PL	
PSUSA/10992	Periodic Safety Update EU Single assessment -	13/06/2024	n/a		PRAC Recommendation - maintenance

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

/202311	tixagevimab / cilgavimab (Evusheld)				
II/0018	Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to update the warning on antiviral resistance, based on the latest neutralisation data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the Product Information. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	30/05/2024	04/10/2024	SmPC, Labelling and PL	Circulating SARS-CoV-2 viral variants may be associated with resistance to monoclonal antibodies such as tixagevimab and cilgavimab. The in vitro neutralisation activity of EVUSHELD against SARS-CoV-2 viral variants are shown in the Summary of the Product Characteristics. Patients who received EVUSHELD prophylactically should be informed of the potential for breakthrough infections to occur. The duration of protection for variants with an observed decrease in in-vitro neutralisation activity is uncertain. Patients should be instructed to promptly seek medical advice if signs or symptoms of COVID-19 occur (the most common symptoms include fever, cough, tiredness and loss of taste or smell; the most serious symptoms include difficulty breathing or shortness of breath, loss of speech or mobility, or confusion and chest pain). Decisions regarding the use of EVUSHELD for the treatment of COVID-19 should take into consideration what is known about the characteristics of the circulating SARS-CoV-2 viral variants, including geographical prevalence.
PSUSA/10992 /202305	Periodic Safety Update EU Single assessment - tixagevimab / cilgavimab (Evusheld)	30/11/2023	n/a		PRAC Recommendation - maintenance
II/0013	C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required	26/10/2023	n/a		

II/0009/G	This was an application for a group of variations. Grouped application comprising two type II variations (REC 23) as follows: C.I.4 - Update of sections 4.4, 4.8 and 5.1 of the SmPC in order to update efficacy and satefy information based on final results from study TACKLE (D8851C00001). C.I.4 - Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update efficacy and safety information based on final results from studies PROVENT (D8850C00002) and STORM CHASER (D8850C00003). In addition, the MAH took the opportunity to add some editorial changes. The RMP version 4.2 is also updated. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	12/10/2023	04/10/2024	SmPC	SmPC new text The PK modelling ,efficacy and safety information included in the SmPC for Evusheld is updated considering the final data analysis coming from PROVENT, STORM CHASER and TACKLE studies. For more information, please refer to the Summary of Product Characteristics.
IAIN/0015	A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release	02/10/2023	04/10/2024	Annex II and PL	
PSUSA/10992 /202211	Periodic Safety Update EU Single assessment - tixagevimab / cilgavimab (Evusheld)	22/06/2023	16/08/2023	SmPC and PL	Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10992/202211.

IB/0012	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	31/07/2023	n/a		
IA/0011	A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)	05/06/2023	n/a		
II/0007/G	This was an application for a group of variations. B.II.f.1.b.4 - Stability of FP - Extension of the shelf life of the finished product - Based on extrapolation of stability data not in accordance with ICH/VICH guidelines B.II.f.1.b.4 - Stability of FP - Extension of the shelf life of the finished product - Based on extrapolation of stability data not in accordance with ICH/VICH guidelines	30/03/2023	16/08/2023	SmPC	The SmPC section 6.3. has been updated as follows: Unopened vial 2 years
II/0006/G	This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test method at the site is a biol/immunol method	16/02/2023	n/a		

PSUSA/10992 /202205	Periodic Safety Update EU Single assessment - tixagevimab / cilgavimab (Evusheld)	01/12/2022	n/a		PRAC Recommendation - maintenance
IB/0005/G	This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits	21/11/2022	n/a		
II/0001	C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one	15/09/2022	16/09/2022	SmPC and PL	Extension of indication to include treatment of adults and adolescents (aged 12 years and older weighing at least 40 kg) with COVID-19, who do not require supplemental oxygen and are at increased risk of progressing to severe COVID-19. As a consequence, sections 4.1, 4.2, 4.4,4.8, 4.9, 5.1, 5.2 ,6.3, 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to make some editorial changes. Version 2.0 of the RMP has also been submitted. Please refer to Scientific Discussion - "Evusheld/H/C/005788/II/0001"

II/0002/G	This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product	15/09/2022	16/09/2022	SmPC and Annex II	